![]() |
|
|
Vol. 286, Issue 3, 1115-1121, September 1998
Department of Preclinical and Clinical Pharmacology, Viale G.B. Morgagni 65, I-50134 Florence, Italy
| |
Abstract |
|---|
|
|
|---|
The effects of the administration of different 5-HT4
receptor antagonists (SDZ 205557, GR 125487) and 5-HT4
receptor agonists (BIMU 1, BIMU 8) on memory processes were evaluated
in the mouse passive avoidance test. The administration of SDZ 205557 (10 mg kg
1 i.p.) and GR 125487 (10 mg kg
1
i.p.) immediately after termination of the training session produced an
amnesic effect. BIMU 1 (20 mg kg
1 i.p.) and BIMU 8 (30 mg
kg
1 i.p.), administered 20 min before the training
session, prevented the 5-HT4 receptor antagonist-induced
amnesia. In the same experimental conditions BIMU 1 (10 mg
kg
1 i.p.; 25 µg/mouse intracerebroventricularly) and
BIMU 8 (30 mg kg
1 i.p.; 30 µg per mouse
intracerebroventricularly) prevented scopolamine (1 mg
kg
1 i.p.) and dicyclomine (2 mg kg
1 i.p.)
amnesia and, at the dose of 10 and 30 mg kg
1 i.p.
respectively, prevented amnesia induced by exposure to a hypoxic
environment. At the highest effective doses, none of the drugs impaired
motor coordination, as revealed by the rota rod test, or modified
spontaneous motility and inspection activity, as revealed by the hole
board and Animex tests. The 5-HT3 antagonist ondansetron
(0.1-1 mg kg
1 i.p.) was unable to prevent scopolamine-,
5-HT4 antagonist- and hypoxia-induced amnesia. These
results suggest that the modulation of 5-HT4 receptors
plays an important role in the regulation of memory processes. On these
bases, the 5-HT4 receptor agonists could be useful in the
treatment of cognitive deficits although 5-HT4 receptor
antagonists may represent pharmacological tools for investigation of
new potential antiamnesic drugs.
| |
Introduction |
|---|
|
|
|---|
The
regulation of synaptic plasticity, which is fundamental in learning and
memory, involves long-term modulation of ion-channel activity.
Stimulation of 5-HT4 receptors may initiate this process by
activation of adenylate cyclase. It has been reported that stimulation
of 5-HT4 receptors increases intracellular cyclic AMP
levels in mouse colliculi neurones (Dumuis et al., 1988
), guinea pig hippocampus (Bockaert et al., 1990
) and human
prefrontal cortex (Monferini et al., 1993
) which then
modulates the activity of protein kinase A (Fagni et al.,
1992
; Ansanay et al., 1995
). In rat hippocampus and in mouse
colliculi neurones, activation of protein kinase A closes potassium
channels. Therefore, reduced after-hyperpolarization may increase
neuronal excitability and ultimately neurotransmitter release (Ansanay
et al., 1995
). Even short exposures (1-2 sec) to
5-HT4 receptor agonists induce long-lasting (2 hr)
inhibition of inward potassium currents.
Early studies demonstrated the ability of metoclopramide, a weak
5-HT4 receptor agonist, to prevent dicyclomine-induced
amnesia in the mouse passive avoidance test (Galeotti et
al., 1993
). Fontana et al. (1994)
, using RS66331, a
5-HT3 receptor antagonist and 5-HT4 receptor
agonist, have reported ameliorative effects in the rat spatial memory
test in which this compound reverted performance deficit produced by
atropine as well as cognitive impairment of aged rats when given alone.
This findings are corroborated by experiments using more selective
5-HT4 receptor agonists. Administration of RS67333, a
highly selective 5-HT4 receptor agonist, suppresses the rat
performance deficit induced by atropine in the Morris water maze, an
effect also reversed by the selective 5-HT4 receptor antagonist RS 67532 (Fontana et al., 1997
). Furthermore,
(R)-zacopride, a weak 5-HT4 receptor agonist with low
affinity for 5-HT3 receptors, exerts marked procognitive
activity (Barnes et al., 1990
). However, the mechanism
underlying this effect of (R)-zacopride is not completely clear,
considering the lack of effect of the more selective 5-HT4 receptor agonist (S)-zacopride (Barnes et al., 1990
).
BIMU 1 and BIMU 8 are two benzimidazolones endowed with
5-HT4 receptor agonistic and 5-HT3 receptor
antagonistic properties (Dumuis et al., 1989
, 1991
; Turconi
et al., 1990
, 1991
). Recent findings suggested that these
compounds have also affinity for
2 receptors (Bonhaus
et al., 1994
; Weatherspoon et al., 1997
). BIMU 1 showed about 1000-fold lower affinity for other serotonin (5-HT1A, 5-HT2A, 5-HT2C), dopamine
(D1 and D2) and muscarinic (M1,
M2, M3 and M4) receptors (Bonhaus
et al., 1993
). Furthermore, the compounds labeled SDZ 205557 and GR 125487 have been reported as selective 5-HT4
receptor antagonists (Buchheit et al., 1991
; Gale et
al., 1994
). By using both the above-mentioned 5-HT4
receptor agonists (BIMU 1 and BIMU 8) and antagonists (SDZ 205557 and
GR 125487), the role of the 5-HT4 receptors in the
modulation of learning and memory processes was investigated in
different passive avoidance paradigms.
| |
Methods |
|---|
|
|
|---|
Animals. Male Swiss albino mice (23-30 g) from Morini (San Polo d'Enza, Italy) were used. The mice were housed 15 per cage. The cages were placed in the experimental room 24 hr before the test for adaptation. The animals were fed a standard laboratory diet and tap water ad libitum and kept at 23 ± 1°C with a 12-hr light/dark cycle, light on at 7 A.M. All experiments were carried out according to the guidelines of the European Community Council for experimental animal care.
Passive-avoidance test.
The test was performed according to
the step-through method described by Jarvik and Kopp (1967)
. The
apparatus consists of a two-compartment acrylic box with a lighted
compartment connected to a darkened one by a guillotine door. Mice, as
soon as they entered the dark compartment, received a punishing
electrical shock (0.5 mA, 1 sec). The latency times for entering the
dark compartment were measured in the training test and after 24 hr in
the retention test. For memory disruption, mice were either exposed to
a hypoxic environment (5%O2 in water-saturated nitrogen) for 8 min up to 30 sec before passive avoidance training or i.p. injected with amnesic drugs. BIMU 1, BIMU 8, ondansetron, physostigmine and piracetam were injected 20 min before the training session while
scopolamine, dicyclomine, GR 125487 and SDZ 205557 were injected
immediately after termination of the training session. The maximum
entry latency allowed in the retention session was 120 sec. The deficit
in passive avoidance performance was expressed as the difference (in
seconds) between retention and training latencies.
Hole board test. The hole board test uses a 40 cm square plane with 16 flush-mounted cylindrical holes (diameter 3 cm) distributed 4 by 4 in an equidistant, grid-like manner. The mice were placed in the center of the board one by one and left to move about freely for a period of 5 min each. Two photoelectric beams, crossing the plane from mid-point to mid-point of opposite sides, thus dividing the plane into four equal quadrants, automatically signaled the movement of the animals on the surface of the plane. Miniature photoelectric cells, in each of the 16 holes, recorded the exploration of the holes (head plunging activity) by the mice.
Rota rod test.
The apparatus consists of a base platform and
a rotating rod of 3-cm diameter with a non-skid surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm in length, was divided into five equal sections by six disks. Thus up to five mice
were tested simultaneously on the apparatus, with a rod-rotation speed
of 16 r.p.m. The integrity of motor coordination was assessed on
the basis of the number of falls from the rod in 30 sec, according to
Vaught et al. (1985)
. Performance time was measured before
and 15, 30 and 45 min after s.c. administration of the drugs.
Spontaneous activity meter (Animex). Locomotor activity in mice was quantified using an Animex activity meter Type S (LKB, Farad, Sweden) set to maximum sensitivity. Mice were placed on the top of the Animex activity meter and each movement produced a signal due to variation in inductance and capacity of the apparatus resonance circuit. These signals were automatically converted to numbers. On the day of the experiment the mice were treated and then the cage, containing five mice, was put on the measurement platform. Activity counts were made every 15 min for 45 min starting immediately after injection of the drug. Because of the arbitrary scale adopted to quantify movements, drug-treated mice were always compared with saline-treated ones.
i.c.v. injection technique.
i.c.v. administration was
performed under ether anesthesia with isotonic saline as a solvent,
according to the method described by Haley and McCormick (1957)
. During
anesthesia, mice were grasped firmly by the loose skin behind the head.
A hypodermic needle (0.4-mm external diameter) attached to a 10-µl
syringe was inserted perpendicularly through the skull and no more than
2 mm into the brain of the mouse, where 5 µl of drug were then
administered. The injection site was 1 mm to the right or left from the
midpoint on a line drawn through to the anterior base of the ears.
Injections were performed randomly into the right or left ventricle. To
ascertain that the drugs were administered exactly into the cerebral
ventricle, some mice were injected with 5 µl of 1:10 diluted India
ink and their brains were examined macroscopically after sectioning.
The accuracy of the injection technique was evaluated and the
percentage of correct injections was 95.
Drugs.
The following drugs were used: BIMU 1, BIMU 8, GR
125487, ondansetron (Boehringer Ingelheim, Milan, Italy), SDZ 205557 prepared in the Department of Pharmaceutical Sciences of University of the Florence according to the method described by Romanelli et al. (1993)
; D-amphetamine (De Angeli, Florence,
Italy); scopolamine hydrobromide, physostigmine hemisulphate, piracetam
(Sigma); dicyclomine hydrochloride (Le Petit).
1 by i.p. injection.
Statistical analysis. All experimental results are given as the means ± S.E.M. Analysis of variance, followed by Fisher's protected least significant difference procedure for post hoc comparison, was used to verify significance between two means. Data were analysed with the StatView software for the Macintosh (1992). P < .05 were considered significant.
| |
Results |
|---|
|
|
|---|
Amnesic effect of 5-HT4 antagonists.
The dose
response curves for SDZ 205557 (1-20 mg kg
1 i.p.) and GR
125487 (0.1-20 mg kg
1 i.p.) in the mouse passive
avoidance test are reported in figure 1.
The two compounds, injected immediately after the training session,
produced deficits in passive-avoidance behavior. This effect was
dose-dependent and statistical significance was reached at the dose of
10 mg kg
1 i.p. Higher doses of SDZ 205557 and GR 125487 were not investigated because the doses of 10 and 20 mg
kg
1 i.p. produced the same degree of behavioral
impairment. The maximum amnesic effect obtained was of the same
intensity of that produced by scopolamine (1 mg kg
1 i.p.)
and dicyclomine (2 mg kg
1 i.p.), used as reference drugs
(fig. 1).
|
Prevention of deficits in passive avoidance behavior by
5-HT4 agonists.
The deficits in passive avoidance
behavior induced by the 5-HT4 antagonists SDZ 205557 (10 mg
kg
1 i.p.) and GR 125487 (10 mg kg
1 i.p.)
was prevented, in the mouse passive avoidance test, by pretreatment
with the 5-HT4 agonists BIMU 1 (20 mg kg
1
i.p.) and BIMU 8 (30 mg kg
1 i.p.), injected 20 min before
the training session. Both 5-HT4 agonists enhanced the
entrance latency up to a value comparable to that produced by control
animals (fig. 2). BIMU 1 and BIMU 8, at 5 and 10 mg kg
1 i.p. respectively, were completely
ineffective (fig. 2).
|
1 i.p.; 25 µg/mouse i.c.v.) and BIMU 8 (30 mg kg
1 i.p.; 30 µg/mouse i.c.v.) were also able to
completely prevent scopolamine (1 mg kg
1 i.p.; figs. 3
and 4) and
dicyclomine (2 mg kg
1 i.p.; fig.
5) induced deficits in passive avoidance
behavior. The doses of 3 mg kg
1 i.p. and 10 µg i.c.v.
BIMU 1 and the doses of 20 mg kg
1 i.p. and 10 µg i.c.v.
BIMU 8 were unable to protect against scopolamine-induced (figs. 3 and
4) and dicyclomine-induced deficits in passive avoidance behavior (fig.
5).
|
|
|
1 i.p. respectively (fig.
6).
|
1 i.p.) and the cholinesterase
inhibitor physostigmine (0.2 mg kg
1 i.p.) as illustrated
in figures 3, 5 and 6.
Doses of BIMU 1 and BIMU 8 higher than 10 and 30 mg kg
1
i.p., respectively, were not investigated because a complete prevention of scopolamine-, dicyclomine- and hypoxia-induced deficits in passive
avoidance behavior used was already reached.
BIMU 1 and BIMU 8, when given alone, at the highest doses used, had no
effect on mouse passive avoidance test in comparison with
saline-treated mice (fig. 3). No statistically significant difference
among the entrance latencies for each compound tested in the training
session of the passive avoidance test was observed (data not shown).
Table 1 reports the entrance latency
values in the training and retention sessions for BIMU 1, BIMU 8, SDZ 205557 and GR 125487 at the highest effective doses, taken as an
example.
|
Lack of effect by the 5-HT3 antagonist
ondansetron.
Ondansetron, up to the dose of 1 mg kg
1
i.p., was not able to prevent scopolamine (1 mg kg
1
i.p.), SDZ 205557 (10 mg kg
1 i.p.) and hypoxia-induced
deficits in passive avoidance behavior (fig.
7).
|
Effect of 5-HT4 agonists and antagonists on mouse rota rod, Animex and hole board tests. It should be noted that the 5-HT4 agonists and antagonists we investigated elicited their modulatory effect on cognitive processes without changing either gross behavior or motor coordination as revealed by the rota rod test (fig. 8). None of the drugs, administered at the highest active doses, increased the number of falls from the rotating rod in comparison with saline- and vehicle-treated mice (fig. 8). The number of falls in the rota rod test progressively decreased because mice learned how to balance on the rotating rod.
|
|
|
| |
Discussion |
|---|
|
|
|---|
5-HT4 receptors appear to be involved in the
regulation of cognitive processes in mice. Our results demonstrate that
the administration of 5-HT4 receptor antagonists (SDZ
205557, GR 125487) provoke amnesia in the mouse passive avoidance test
of severity comparable to that induced by the amnesic drugs scopolamine
and dicyclomine. The 5-HT4 receptor agonists (BIMU 1, BIMU
8) are able to prevent the amnesia induced not only by
5-HT4 receptor antagonists, but also by antimuscarinic
drugs and exposure to a hypoxic environment. Previous data,
demonstrating the amelioration in rats of social olfactory memory
(Letty et al., 1997
) and associative memory
(Marchetti-Gauthier et al., 1997
) produced by the
5-HT4 agonist BIMU 1, confirmed our results.
BIMU 1 and BIMU 8 have been reported to be endowed also with
5-HT3 receptor antagonistic activity (Turconi et
al., 1990
, 1991
). However, their procognitive effect seems
unrelated to the blockade of 5-HT3 receptors because
ondansetron, a highly selective 5-HT3 receptor antagonist
(Turconi et al., 1991
), did not exert any effect on
hypoxia-, scopolamine- and 5-HT4 antagonists-induced amnesia. The lack of improvement of social olfactory memory in rats by
ondansetron (Letty et al., 1997
) confirms the hypothesis that 5-HT3 receptors are not involved in the regulation of
memory processes.
5-HT4 receptors have a restricted distribution in guinea
pig and human brains, suggesting that they have specific functions and
indicating that they play a role in neuronal excitability and
neurotransmitter release. Rat interpeduncular nucleus, thalamus and
hippocampus contain a high degree of 5-HT4 receptors
(Waeber et al., 1993
). At the hippocampal level the
distribution is clearly laminar along the pyramidal cell layers CA1,
CA2, CA3 and dentate gyrus (Waeber et al., 1993
). In the
human brain 5-HT4 receptors have been observed in the
frontal cortex, superior colliculi, limbic structures and basal ganglia
(Waeber et al., 1993
; Grossman et al., 1993
). A
high density of 5-HT4 receptors have been observed especially in the nigro-striatal pathway and hippocampus (Waeber et al., 1993
). The location of 5-HT4 receptors
in the hippocampus from several species is also consistent with a role
for the receptor in cognitive processes (Bockaert et al.,
1994a
; Letty et al., 1997
; Marchetti-Gautier et
al., 1997
; Fontana et al., 1997
). 5-HT4 receptor activation has been found to inhibit after-hyperpolarization in rat CA1 hippocampal neurones and such effects may contribute to the
induction of long-term potentiation, an elementary biochemical and
cellular process for learning and memory (Andrade and Chaput, 1991
). In
mouse colliculi neurones, moreover, 5-HT4 receptor agonism elevates intracellular adenylyl cyclase and, consequently, inhibits voltage-sensitive potassium channel opening time (Dumuis et
al., 1989
; Andrade and Chaput, 1991
; Bockaert et al.,
1994a
, b
). Prolonged closure of potassium channels, and thus neuronal
hyperexcitability, was seen even after very short exposure to 5-HT
(Bockaert et al., 1994b
). These mechanisms may be involved
in the induction of hippocampal CA1 late stage long-term potentiation
(Frey et al., 1993
), a potential mechanism for explicit
forms of memory. Furthermore, a marked loss of 5-HT4
receptors, labeled with [3H]-GR 113808, in hippocampal
and cortical regions in the brains of patients with Alzheimer's
disease (Reynolds et al., 1995
) supports the hypothesis of a
role for 5-HT4 receptors in memory processes.
An in vivo study indicated that i.c.v. injection of
zacopride and renzapride, two 5-HT4 agonists, increased the
energy of low frequency hippocampal theta rhythm and other frequency
bands (Boddeke and Kalkman, 1990
). These effects were blockaded by
scopolamine, suggesting a cholinergic step in the effects of
5-HT4 agonists. The involvement of the cholinergic system
in the central effects of 5-HT4 agonists was confirmed by
rat microdialysis studies in which an increase in ACh extracellular
levels was observed after BIMU 1 and BIMU 8 administration (Consolo
et al., 1994
). Furthermore, Ghelardini et al.
(1996)
demonstrated that the antinociceptive effect of BIMU 1 and BIMU
8 is mediated via activation of cholinergic neurotransmission. Because
it has long been known that the stimulation of the cholinergic system
improves cognitive processes (Coyle, 1995
) the facilitatory effect
induced by the 5-HT4 agonists BIMU 1 and BIMU 8 could be
due, at least in part, to activation of the cholinergic system.
BIMU 1 and BIMU 8 exerted their antiamnesic effect by acting centrally. It was possible to reach the same intensity of analgesia by injecting directly into the cerebral ventricles doses (25-30 µg/mouse) of BIMU 1 and BIMU 8 which were much lower than those needed parenterally. This finding excludes the possibility that the antiamnesic action can depend on retrodiffusion of the two 5-HT4 agonists from the cerebral ventricles to the periphery.
The 5-HT4 receptor agonists BIMU 1 and BIMU 8 have been
reported to be endowed with analgesic properties (Ghelardini et
al., 1996
). In our experimental conditions these compounds were
administered before receiving the punishing stimulus in correspondence
with their maximum antinociceptive activity. It is, however, unlikely that their analgesic effect may have influenced the results obtained. Analgesic drugs, by reducing the perception of the punishing stimulus (electric shock), may produce a false amnesic effect. BIMU 1 and BIMU
8, even at the highest doses used, were always able to prevent amnesia
indicating that the degree of antinociception produced was insufficient
to reduce the perception of the electric shock applied.
The 5-HT4 receptor agonists and antagonists, at the highest doses used, did not modify the animals' gross behavior. Nor did these compounds impair motor coordination as revealed by the rota rod test or modify locomotor and inspection activity as indicated by the hole board and Animex tests. We can, thus, suppose that the effects produced by 5-HT4 receptor modulators were not imputable to compromised viability. Higher doses of all compounds were not investigated because the maximum amnesic (SDZ 205557, GR 125487) and antiamnesic (BIMU 1, BIMU 8) effect was already reached.
In conclusion, these results indicate the important role played by 5-HT4 receptors in the regulation of memory processes. On these bases, the 5-HT4 receptor agonists could be useful in the treatment of cognitive deficits although 5-HT4 receptor antagonists may represent pharmacological tools for investigation of new potential antiamnesic drugs.
| |
Acknowledgments |
|---|
The authors thank Mary Forrest for linguistic revision of the manuscript.
| |
Footnotes |
|---|
Accepted for publication April 9, 1998.
Received for publication July 15, 1997.
1 This study was supported by grants from MURST.
Send reprint requests to: Dr. Carla Ghelardini, Department of Pharmacology, Viale G.B. Morgagni 65, I-50134 Florence, Italy.
| |
Abbreviations |
|---|
i.c.v., intracerebroventricular; BIMU 1, (endo-N-(8-methyl-8-azabicyclo[3.2.1]-oct-yl)-2,3-dihydro-3-ethyl-2-oxo-1H-benzimidazol-1 carboxamide hydrochloride) ; BIMU 8, (endo-N-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-2,3-dihydro-(1-methyl)ethyl-2-oxo-1H-benzimidazol-1 carboxamide hydrochloride) ; SDZ 205557, (2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino) ethyl ester hydrochloride); GR 125487, [1-[2(methylsufonyl)amino]ethyl]-4-piperidinyl] methyl-5-fluoro-2-methoxy-1H-indole-3-carboxylate hydrochloride ; 5-HT, 5-hydroxytryptamine.
| |
References |
|---|
|
|
|---|
2 binding sites in guinea-pig hippocampus.
J Pharmacol Exp Ther
267:
961-970
1 but not
2 binding sites in guinea-pig brain.
J Pharmacol Exp Ther
271:
484-493
2 receptors.
Eur J Pharmacol
326:
133-138[Medline].
This article has been cited by other articles:
![]() |
M. Orsetti, A. Dellarole, S. Ferri, and P. Ghi Acquisition, Retention, and Recall of Memory After Injection of RS67333, a 5-HT4 Receptor Agonist, Into the Nucleus Basalis Magnocellularis of the Rat Learn. Mem., September 1, 2003; 10(5): 420 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Moser, O. E. Bergis, S. Jegham, A. Lochead, E. Duconseille, J.-P. Terranova, D. Caille, I. Berque-Bestel, F. Lezoualc'h, R. Fischmeister, et al. SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 731 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Matsumoto, H. Togashi, K. Mori, K.-i. Ueno, S. Ohashi, T. Kojima, and M. Yoshioka Evidence for Involvement of Central 5-HT4 Receptors in Cholinergic Function Associated with Cognitive Processes: Behavioral, Electrophysiological, and Neurochemical Studies J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 676 - 682. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||